{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:08:58Z","timestamp":1793164138783,"version":"4.5.0"},"reference-count":30,"publisher":"Korean Diabetes Association","issue":"3","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Hyundai Pharmaceutical Co. Ltd."}],"content-domain":{"domain":["e-dmj.org"],"crossmark-restriction":true},"short-container-title":["Diabetes Metab J"],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:p>Background: This study assessed the efficacy and safety of HD-6277, a novel oral G protein-coupled receptor 40 (GPR40) agonist in adults with inadequate control of type 2 diabetes mellitus (T2DM).Methods: This double-blind, randomized, placebo-controlled phase 2 trial recruited 112 individuals aged 18\u201375 years with T2DM and glycosylated hemoglobin (HbA1c) levels between 7.0% and 10.0% while on diet and exercise alone for at least 8 weeks before screening. Parallel-group randomized trials of HD-6277 (50 and 100 mg groups vs. placebo) were conducted for 12 weeks. The primary outcome was the change in HbA1c levels from baseline to week 12. Secondary outcomes included changes in HbA1c, fasting plasma glucose (FPG), postprandial glucose, insulin, glycoalbumin, and C-peptide at weeks 4, 8, and 12.Results: At week 12, HD-6277 at 50 and 100 mg demonstrated statistically significant reductions in HbA1c compared to placebo, with least square (LS) mean differences of \u20130.73% (95% confidence interval [CI], \u20131.11 to \u20130.35; &lt;i&gt;P&lt;\/i&gt;=0.0002) and \u20130.85% (95% CI, \u20131.21 to \u20130.50; &lt;i&gt;P&lt;\/i&gt;&lt;0.0001), respectively. Both doses also produced clinically meaningful reductions in FPG. Additionally, HD- 6277 at 100 mg significantly increased the insulinogenic index compared to placebo, with an LS mean difference of 1.91 (95% CI, 0.34 to 3.48; &lt;i&gt;P&lt;\/i&gt;=0.0175). No clinically relevant treatment-related adverse events were observed.Conclusion: HD-6277 at 50 and 100 mg improved glycemic control and was well-tolerated in adults with T2DM inadequately managed with diet and exercise. GPR40 agonists may offer a promising new therapeutic option for T2DM.<\/jats:p>","DOI":"10.4093\/dmj.2025.0528","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:00:39Z","timestamp":1766023239000},"page":"576-586","update-policy":"https:\/\/doi.org\/10.4093\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of HD-6277, a Novel G Protein-Coupled Receptor 40 Agonist, in Individuals with Type 2 Diabetes Mellitus: A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Clinical Trial"],"prefix":"10.4093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6219-4942","authenticated-orcid":true,"given":"Yong-ho","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"},{"name":"Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea"},{"name":"Institute for Innovation in Digital Healthcare (IIDH), Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Wan","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Nowon Eulji Medical Center, Eulji University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Hwa","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Daejeon Eulji Medical Center, Eulji University, Daejeon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Myung","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choon Hee","family":"Chung","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Research Institute of Metabolism and Inflammation, Yonsei University Wonju College of Medicine, Wonju, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Sung","family":"Moon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Chul","family":"Won","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Gimpo Woori Hospital, Gimpo, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Woo","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Nyun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Inje University College of Medicine, Busan, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9899-4992","authenticated-orcid":true,"given":"Byung-Wan","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea"},{"name":"Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2567","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.528"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92814-v"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-024-00824-9"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2018.42.2.93"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2022.0106"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.30926"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01530-9"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2014.38.3.197"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2024.0818"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.10.161"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dcs13-2037"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m211495200"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2337\/db21-0711"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.43"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(11)61879-5"},{"key":"ref16","first-page":"622","volume-title":"GPR40 agonists for the treatment of type 2 diabetes: life after \u2018TAKing\u2019 a hit","author":"Mancini","year":"2015"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12838"},{"key":"ref18","first-page":"16","volume-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","author":"Neeland","year":"2024"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13805"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2337\/db18-1202-p"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0076280"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0872"},{"key":"ref23","first-page":"853","volume-title":"Efficacy and safety of HD-6277, a novel GPR40 agonist, in patients with type 2 diabetes: a double-blind, randomized, placebo-controlled, parallel-group, multicenter phase 2 trial","author":"Lee","year":"2024"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-0666"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-0706"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.2337\/db23-0613"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.4.796"},{"key":"ref28","first-page":"1789","volume-title":"Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis","author":"Kodama","year":"2013"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(15)00389-7"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(15)00336-8"}],"container-title":["Diabetes &amp; Metabolism Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2025-0528.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2025.0528","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-dmj.org\/upload\/pdf\/dmj-2025-0528.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T07:58:12Z","timestamp":1778486292000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-dmj.org\/journal\/view.php?doi=10.4093\/dmj.2025.0528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"URL":"https:\/\/doi.org\/10.4093\/dmj.2025.0528","relation":{},"ISSN":["2233-6079","2233-6087"],"issn-type":[{"value":"2233-6079","type":"print"},{"value":"2233-6087","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"2025-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-19","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}